{
  "docId": "019de070-cb6f-702e-8ba7-38c2ee57750d",
  "docSlug": "70846fe5de6d20355c3868d80f4845b0",
  "documentTitle": "BioNTech | Results Presentation Deck | 36 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 36,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "The slide uses a 2x3 grid layout to present organizational milestones.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-cb6f-702e-8ba7-38c2ee57750d/6",
  "deckHref": "/decks/019de070-cb6f-702e-8ba7-38c2ee57750d",
  "deckJsonHref": "/decks/019de070-cb6f-702e-8ba7-38c2ee57750d.json",
  "deckAnchorHref": "/decks/019de070-cb6f-702e-8ba7-38c2ee57750d#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.92,
        "x": 0.04,
        "y": 0.2
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ac74d963-d293-4918-9224-02005c5026ac",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.28,
        "x": 0.04,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "First Product Launch: BNT162b2 launched globally. Authorized for use in >65 countries with >200M doses delivered*",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "03d42f8a-3b6c-4f2c-b907-3451bcf90eee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.28,
        "x": 0.36,
        "y": 0.55
      },
      "kind": "paragraph",
      "text": "Product Opportunities: Advancing product opportunities in oncology. 3 cancer immunotherapies to enter trials with registrational potential in 2021",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "53d7e9d7-b0a5-40e2-b95d-71f87ddbf97a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.28,
        "x": 0.68,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "Manufacturing: Acquired commercial-scale GMP facility. Own mRNA manufacturing network with up to 1 billion dose annual capacity",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "59f2e5e3-1e08-4062-b2ce-7b4828f8c6b3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.28,
        "x": 0.68,
        "y": 0.55
      },
      "kind": "paragraph",
      "text": "Global Footprint: Grew to >1,900 employees with >600 in R&D. Expanded sites in Germany and established U.S. HQ in Cambridge, MA via acquisition of Neon Therapeutics",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "764ef567-867d-4280-b22b-d2be72f1c5e0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.28,
        "x": 0.04,
        "y": 0.55
      },
      "kind": "paragraph",
      "text": "Broadened Pipeline: Broadened clinical-stage pipeline to 14 ongoing clinical trials. 13 clinical stage product candidates across 4 drug classes",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a8ceceed-b6a1-46c2-a62f-a41842db4615",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.28,
        "x": 0.36,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "Commercial: Established first sales force. Successful commercial launch in Germany with BioNTech sales team",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cdc01530-1a2b-40d9-b914-16bc3ea7baa6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.15,
        "x": 0.08,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "* as of March 23, 2021",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d5f5c01-b26a-4579-8e9d-6eb25265cbaf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.04,
        "y": 0.09
      },
      "kind": "title",
      "text": "BioNTech's capabilities were transformed in 2020",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9f9ce34e-d7e2-4116-a061-4f2c6b87f0c6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "4bf4ba3a-a51b-400f-8b53-29b286ed87f1",
      "evidence": "Global Footprint: Grew to >1,900 employees with >600 in R&D.",
      "confidence": 0.7
    },
    {
      "name": "Three Pillars",
      "slug": "three-pillars",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "30a135f6-d693-44f5-9608-1befc5328499",
      "evidence": "Product Opportunities: Advancing product opportunities in oncology. 3 cancer immunotherapies to enter trials with registrational potential in 2021",
      "confidence": 0.5
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 8,
      "from": 5,
      "beatId": "ea16b6bf-4fff-47c2-ac41-4f78876cafc0",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "Key Takeaways",
      "beatSlug": null,
      "evidence": "The document highlights BioNTech's capabilities and progress in 2020",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}